DE69633449D1 - Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten - Google Patents

Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten

Info

Publication number
DE69633449D1
DE69633449D1 DE69633449T DE69633449T DE69633449D1 DE 69633449 D1 DE69633449 D1 DE 69633449D1 DE 69633449 T DE69633449 T DE 69633449T DE 69633449 T DE69633449 T DE 69633449T DE 69633449 D1 DE69633449 D1 DE 69633449D1
Authority
DE
Germany
Prior art keywords
lung
acceptable salt
sample
mucus
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633449T
Other languages
English (en)
Other versions
DE69633449T2 (de
Inventor
C Boucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
University of North Carolina System
Original Assignee
University of North Carolina at Chapel Hill
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, University of North Carolina System filed Critical University of North Carolina at Chapel Hill
Publication of DE69633449D1 publication Critical patent/DE69633449D1/de
Application granted granted Critical
Publication of DE69633449T2 publication Critical patent/DE69633449T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
DE69633449T 1995-07-31 1996-07-24 Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten Expired - Fee Related DE69633449T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US509052 1995-07-31
US08/509,052 US5628984A (en) 1995-07-31 1995-07-31 Method of detecting lung disease
PCT/US1996/012377 WO1997005195A1 (en) 1995-07-31 1996-07-24 Method of detecting lung disease

Publications (2)

Publication Number Publication Date
DE69633449D1 true DE69633449D1 (de) 2004-10-28
DE69633449T2 DE69633449T2 (de) 2006-04-27

Family

ID=24025091

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633449T Expired - Fee Related DE69633449T2 (de) 1995-07-31 1996-07-24 Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten

Country Status (17)

Country Link
US (4) US5628984A (de)
EP (1) EP0841900B1 (de)
JP (2) JP3623237B2 (de)
KR (1) KR100283306B1 (de)
CN (1) CN1121441C (de)
AT (1) ATE276740T1 (de)
AU (1) AU705528B2 (de)
BR (1) BR9610059A (de)
CA (1) CA2226892A1 (de)
DE (1) DE69633449T2 (de)
ES (1) ES2229281T3 (de)
IL (1) IL122803A0 (de)
MX (1) MX9800933A (de)
NO (1) NO980279L (de)
NZ (1) NZ313864A (de)
WO (1) WO1997005195A1 (de)
ZA (1) ZA966425B (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
ATE210466T1 (de) * 1995-04-13 2001-12-15 Milkhaus Lab Inc Methoden zur behandlung von atemwegserkrankungen
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
US6998121B2 (en) 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
WO1999005155A2 (en) 1997-07-25 1999-02-04 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
KR20010023359A (ko) * 1997-08-29 2001-03-26 인스파이어 파마슈티컬즈 폐질환 치료용 우리딘 5'-디포스페이트 및 그의 유사체의용도
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
EP1139746A4 (de) * 1998-12-22 2003-09-17 Univ North Carolina Verbindungen und verfahren zur behandlung von atemwegserkrankungen sowie zur verabreichung von arzneistoffen für die atmewege
ATE281837T1 (de) 1999-02-26 2004-11-15 Inspire Pharmaceuticals Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
GB2394419B (en) 2001-06-25 2005-09-07 Inspire Pharmaceuticals Inc Joint lubrication with p2y purinergic receptor agonists
JP3823162B2 (ja) * 2001-07-31 2006-09-20 株式会社エイアンドティー 臨床検査分析装置、臨床検査分析方法および臨床検査分析プログラム
JP2005532254A (ja) * 2001-11-06 2005-10-27 インスパイアー ファーマシューティカルズ，インコーポレイティド 炎症性疾患を治療又は予防する方法
US20060196365A1 (en) * 2001-12-11 2006-09-07 Garman Michael H Combined water cooler and hot beverage maker
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
AU2003243191B2 (en) 2002-05-02 2007-09-20 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
JP2007524379A (ja) * 2003-03-31 2007-08-30 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 上皮ナトリウムチャンネル関連障害のＰｈａｒｍｉｃｏ−遺伝子治療
KR101153254B1 (ko) 2003-06-26 2012-07-02 바이오트론 리미티드 항바이러스 화합물 및 방법
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
CN1886367A (zh) * 2003-11-24 2006-12-27 北卡罗来纳大学查珀尔希尔分校 稠环双阳离子抗原生动物药物及其前药
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
WO2005086754A2 (en) * 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc. Dicationic compounds for activity against trichomonas vaginalis
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
WO2006096757A2 (en) * 2005-03-07 2006-09-14 The University Of North Carolina At Chapel Hill Inhibitors of reca activities for control of antibiotic-resistant bacterial pathogens
AU2006201739A1 (en) * 2005-05-05 2006-11-23 The University Of North Carolina At Chapel Hill Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
WO2006125153A2 (en) * 2005-05-18 2006-11-23 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
AU2006202083A1 (en) * 2005-06-03 2006-12-21 Reto Brun Linear dicationic terphenyls and their aza analogues as antiparasitic agents
US7964619B2 (en) 2005-06-03 2011-06-21 The University Of North Carolina At Chapel Hill Teraryl components as antiparasitic agents
US20100249175A1 (en) * 2005-12-02 2010-09-30 Wilson W David Dicationic compounds which selectively recognize G-quadruplex DNA
EP2019964A2 (de) * 2006-04-28 2009-02-04 University of Iowa Research Foundation Verfahren und verbindungen zur modulation der parvovirusübertragung von säugerzellen oder zur änderung von virusinfektionen verfahren zur identifizierung eines viralen rezeptors oder co-rezeptors
US20080260863A1 (en) * 2007-04-20 2008-10-23 Pre Holding, Inc. Compositions for mucociliary clearance and methods for administering same
AU2008266856A1 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of PFKFB3 inhibitors with anti-neoplastic activities
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009051796A2 (en) * 2007-10-17 2009-04-23 The University Of North Carolina At Chapel Hill 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents
EA201001450A1 (ru) 2008-04-09 2011-08-30 Зе Юнивёсэти Оф Ноф Кэрэлайн Эт Чэпл Хил Способы регулирования реаранжировки актинового цитоскелета и формирования межклеточных промежутков
WO2010039997A2 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
EP2341906A4 (de) 2008-10-01 2012-06-13 Univ North Carolina Hämatopoietischer schutz gegen ionisierungsstrahlung mithilfe selektiver cyclin-abhängiger kinase-4/6-hemmer
CA2754691C (en) 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
AU2010248886A1 (en) 2009-05-13 2011-12-01 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
ES2824842T3 (es) 2009-07-13 2021-05-13 Patheon Api Services Inc Síntesis de prostanoides
EP2461805B1 (de) 2009-07-24 2017-11-01 University of Tennessee Research Foundation Spectinamide als mittel gegen tuberkulose
KR20120050475A (ko) * 2009-08-10 2012-05-18 피투-사이언스 에이피에스 협착증 및 제한된 혈류의 기타 상태를 진단하기 위한 ｕｔｐ
JP5922111B2 (ja) * 2010-06-23 2016-05-24 ピーツー−サイエンス・エペイエス 充血剤注入と同時に血圧測定を行う診断目的の動脈用複合カテーテル
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
EP2464346A1 (de) 2010-08-30 2012-06-20 Pulmatrix, Inc. Behandlung zystischer fibrose mit calciumlactat, leukin und natriumchlorid in einem einatembaren trockenpulver
EP4008326A1 (de) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Einwertige metallkationen-trockenpulver zum inhalieren
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
CN103732213A (zh) * 2011-06-07 2014-04-16 帕里昂科学公司 治疗方法
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
US9833207B2 (en) 2012-08-08 2017-12-05 William Harrison Zurn Analysis and clearing module, system and method
AU2013363218B2 (en) 2012-12-17 2018-03-15 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9029382B2 (en) 2012-12-17 2015-05-12 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
US9962533B2 (en) 2013-02-14 2018-05-08 William Harrison Zurn Module for treatment of medical conditions; system for making module and methods of making module
HUE046653T2 (hu) 2013-03-15 2020-03-30 G1 Therapeutics Inc Normál sejtek tranziens védelme kemoterápia során
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
WO2015048736A1 (en) 2013-09-30 2015-04-02 Irix Pharmaceuticals, Inc. Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015161287A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of normal cells during chemotherapy
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN104306028B (zh) * 2014-09-26 2016-08-17 张清玲 一种用于呼吸道细菌16S rRNA基因序列检测的痰液收集方法
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
WO2018005860A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
US10413583B2 (en) 2016-11-30 2019-09-17 The University Of Chicago Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3985002A1 (de) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Aryl-, heteroaryl- und heterocyclische verbindungen zur behandlung von medizinischen erkrankungen
GB2604314A (en) * 2017-09-22 2022-09-07 Nerudia Ltd Device, system and method
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3847174A4 (de) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. Morphische formen von komplementfaktor-d-inhibitoren
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055465A (en) * 1962-09-27 1967-01-18 Vantorex Ltd Allergenic aerosol compositions
NL299931A (de) * 1962-10-30
US4132600A (en) * 1977-06-01 1979-01-02 Massachusetts Institute Of Technology Enzymatic noninvasive method for detecting cancer
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
FR2571257A1 (fr) * 1984-08-06 1986-04-11 Gros Pierre Composition destinee a l'humidification de la muqueuse rhino-pharyngee
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US4950477A (en) * 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (de) * 1991-06-05 1992-12-09 Synthelabo Pharmazeutische Zusammensetzungen zur Behandlung von Atemwegserkrankungen
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
US6133247A (en) 2000-10-17
CN1191553A (zh) 1998-08-26
ATE276740T1 (de) 2004-10-15
EP0841900B1 (de) 2004-09-22
JPH11509759A (ja) 1999-08-31
BR9610059A (pt) 1999-03-02
DE69633449T2 (de) 2006-04-27
NO980279D0 (no) 1998-01-21
CN1121441C (zh) 2003-09-17
AU6639996A (en) 1997-02-26
AU705528B2 (en) 1999-05-27
KR19990036011A (ko) 1999-05-25
US5902567A (en) 1999-05-11
US6214536B1 (en) 2001-04-10
US5628984A (en) 1997-05-13
WO1997005195A1 (en) 1997-02-13
MX9800933A (es) 1998-05-31
CA2226892A1 (en) 1997-02-13
NO980279L (no) 1998-01-21
EP0841900A1 (de) 1998-05-20
ES2229281T3 (es) 2005-04-16
JP2003073280A (ja) 2003-03-12
IL122803A0 (en) 1998-09-16
NZ313864A (en) 2000-04-28
ZA966425B (en) 1997-02-19
JP3623237B2 (ja) 2005-02-23
EP0841900A4 (de) 1998-06-10
KR100283306B1 (ko) 2001-03-02

Similar Documents

Publication Publication Date Title
DE69633449D1 (de) Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
JP2000514461A (ja) ウリジン・トリホスフェート及び関連化合物による副鼻腔炎の治療方法
CA2250188A1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
ATE225663T1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
Rubin et al. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis
CA2147469A1 (en) Compaction assay for assessment of respiratory disease therapy
Slocombe et al. Evaluation of ivermectin against later fourth-stage Strongylus vulgaris in ponies at two and five weeks after treatment.
KR890012942A (ko) 5-치환된 오르니틴 유도체
Fluur et al. Gout in the temporomandibular joint: report on a case
JP2008127346A (ja) 自己免疫疾患、炎症および神経疾患を治療および予防するための医薬
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
Buss et al. Visceral herpesvirus infections in leukemic patients receiving cytarabine
Braga et al. Preliminary data on the action of nesosteine, a mucomodifying drug, on mucociliary transport
Rivera Acute histoplasmosis: a modern appraisal
Kuznetsov et al. Case of Kawasaki's disease in the maritime territory
Gewirtz The intravenous drug abuse patient
Bishara et al. Lichenoid reaction in bone marrow transplants suffering from chronic GVHD is associated with HLA-DQW1
Hartzell Pyorrhea Alveolaris: Its Etiology and Treatment
王小马 ELECTROIMPULSE ACUPUNCTURE TREATMENT OF 110 CASES OF ABDOMINAL PAIN AS A SEOUELA OF ABDOMINAL SURGERY
Shahan et al. LAURA K. RICHMAN AND RICHARD J. MONTALI
Herman Herd Tachyphylaxis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee